Skip to main content
SpringerLink
Log in
Book cover

Adjuvant Therapy for Breast Cancer pp 3–12Cite as

History of Adjuvant Therapy

  • Chapter
  • First Online:

  • 1368 Accesses

Part of the book series: Cancer Treatment and Research ((CTAR,volume 151))

Breast cancer is a significant public health problem in virtually all industrialized societies. In many developed countries it is the most common life-threatening malignancy and the second most frequent cause of cancer-related mortality. After peaking in the 1990s, and despite a gradual increase in incidence [1], the overall mortality for breast cancer has been declining in the United States and in some European countries [1, 2].

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   279.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Jemal A, Siegel R, Ward E. Cancer statistics. CA Cancer J Clin. 2006;56:106–30.

    Article  PubMed  Google Scholar 

  2. Peto R, Boreham J, Clarke M, et al. UK and USA breast cancer deaths down 25% in year 2000 at ages 20–69 years. Lancet. 2000;355:1822.

    Article  PubMed  CAS  Google Scholar 

  3. Kinne D. Primary treatment of breast cancer. In: Harris JR, Helman S, Henderson IC, et al., eds. Breast Diseases. Philadelphia, PA, Lippincott; 1991:347–73.

    Google Scholar 

  4. Halsted WS. The results of radical operations for the cure of carcinoma of the breast. Ann Surg. 1907;46:1–19.

    Article  PubMed  CAS  Google Scholar 

  5. Fisher B, Fisher ER. The interrelationship of hematogenous and lymphatic tumor cell dissemination. Surg Gynecol Obstet. 1966;122:791–98.

    PubMed  CAS  Google Scholar 

  6. Fisher B. The evolution of paradigms for the management of breast cancer: A personal perspective. Cancer Res. 1992;52:2371–83.

    PubMed  CAS  Google Scholar 

  7. Skipper HE, Schabel FM Jr. Tumor stem cell heterogeneity: Implication with respect to the classification of cancers by chemotherapeutic effect. Cancer Treat Rep. 1984;68:43–61.

    PubMed  CAS  Google Scholar 

  8. Griswold DP Jr. Body burden of cancer in relationship to therapeutic outcome: Consideration of preclinical evidence. Cancer Treat Rep. 1986;70:81–6.

    PubMed  CAS  Google Scholar 

  9. Martin DS, Fugman RA, Stolfi RL, Hayworth PE. Solid tumor animal model therapeutically predictive for human breast cancer. Cancer Chemother Rep. 1975;5:89–109.

    Google Scholar 

  10. Henderson IC. Adjuvant endocrine therapy. In: J Allegra, ed. Management of Breast Cancer through Endocrine Therapies. Amsterdam: Excerpta Medica; 1984:38–57.

    Google Scholar 

  11. Pritchard KI. Current status of adjuvant endocrine therapy for resectable breast cancer. Semin Oncol. 1987;14:23–33.

    PubMed  CAS  Google Scholar 

  12. Early Breast Cancer Trialists’ Collaborative Group. Ovarian ablation in early breast cancer: Overview of the randomised trials. Lancet. 1996;348:1189–96.

    Article  Google Scholar 

  13. Nolvadex Adjuvant trial organization. Controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer. Analysis of six years. Lancet. 1985;1:836–40.

    Google Scholar 

  14. Early Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet. 2005;365:1687–717.

    Article  Google Scholar 

  15. Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: Updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst. 2001;93:456–62.

    Article  Google Scholar 

  16. Stewart HJ, Prescott RJ, Forrest AP. Scottish adjuvant tamoxifen trial: A randomized study updated to 15 years. J Natl Cancer Inst. 2001:93:456–62.

    Article  PubMed  CAS  Google Scholar 

  17. Peto R, Davies C and the ATLAS investigators. ATLAS (Adjuvant Tamoxifen, Longer Against Shorter): International randomized trials of 10 versus 5 years of adjuvant tamoxifen among 11,500 women: Preliminary results. In: Program and Abstracts of the 30th Annual San Antonio Breast Cancer Symposium; San Antonio, Texas (abstract 48).

    Google Scholar 

  18. Gray RG, Rea DW, Handley K, et al. aTTom adjuvant Tamoxifen – To offer more?: Randomized trial of 10 versus 5 years of adjuvant tamoxifen among 6,934 women with estrogen receptor-positive (ER+) or ER untested breast cancer – preliminary results. Proc Am Soc Clin Oncol, 26, 2008 (abstract 513).

    Google Scholar 

  19. Osborne CK. Effects of estrogen and antiestrogens on cell proliferation. In: Osborne CK, Ed. Endocrine Treatment in Breast and Prostate Cancer. Boston, MA: Kluwer; 1988:11–129.

    Chapter  Google Scholar 

  20. Berman E, Adams M, Duigou-Osterndorf R, et al. Effect of tamoxifen on cell lines displaying the multidrug-resistant phenotype. Blood. 1991:77:818–25.

    PubMed  CAS  Google Scholar 

  21. Bonadonna G, Valagussa P, Veronesi U. Results of ongoing clinical trials with adjuvant chemotherapy in operable breast cancer. In: Heuson JC, Mattheiem WH, Rozencweig M, eds. Breast Cancer Trends in Research and Treatment. New York, NY: Raven Press; 1976:239–58.

    Google Scholar 

  22. Fisher B, Carbone P, Economou SG, et al. L-Phenylalanine mustard (L-PAM) in the management of primary breast cancer: A report of early findings. N Engl J Med. 1975; 292:117–22.

    Article  PubMed  CAS  Google Scholar 

  23. Bonadonna G, Brusamolino E, Valagussa P, et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med. 1976:294:405–10.

    Article  PubMed  CAS  Google Scholar 

  24. Bonadonna G, Moliterni A, Zambetti M, et al. 30 years’ follow up of randomized studies of adjuvant CMF in operable breast cancer: Cohort study. BMJ. 2005;330:217–23.

    Article  PubMed  Google Scholar 

  25. Bonadonna G, Zambetti M, Moliterni A, et al. Clinical relevance of different sequencing of doxorubicin and cyclophosphamide, methotrexate, and fluorouracil in operable breast cancer. J Clin Oncol. 2004;22:1614–20.

    Article  PubMed  CAS  Google Scholar 

  26. Dang C, Hudis C. Adjuvant taxanes in the treatment of breast cancer: No longer at the tip of the iceberg. Clin Breast Cancer. 2006;7:51–8.

    Article  PubMed  CAS  Google Scholar 

  27. Poole CJ, Earl HM, Hiller L, et al. Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer. N Engl J Med. 2006;355:1851–62.

    Article  PubMed  CAS  Google Scholar 

  28. Bonadonna G, Hortobagyi GN, Valagussa P. Individualized therapy of breast cancer: A dream or a reality? In: Bonadonna G, Hortobagyi GN, Valagussa P, eds. Textbook of Breast Cancer. A Clinical Guide to Therapy. 3rd ed. London New York: Taylor & Francis; 2006:395–99.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Operations Office, Fondazione Michelangelo, Milano, Italy

    Pinuccia Valagussa

Authors
  1. Pinuccia Valagussa
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Inselspital, Univ. Bern, Bern, 3010, Switzerland

    Monica Castiglione

  2. Inst. Jules Bordet, Universite Libre Bruxelles, Bd. de Waterloo 125, Bruxelles, 1000, Belgium

    Martine J. Piccart

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Valagussa, P. (2009). History of Adjuvant Therapy. In: Castiglione, M., Piccart, M. (eds) Adjuvant Therapy for Breast Cancer. Cancer Treatment and Research, vol 151. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-75115-3_1

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-75115-3_1

  • Published:

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-0-387-75114-6

  • Online ISBN: 978-0-387-75115-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation